US EditionExclusive: Duke spinout launches in hopes of prevailing with brain cancer bispecific where Amgen, Roche did not
Summary by Endpoints News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Exclusive: Duke spinout launches in hopes of prevailing with brain cancer bispecific where Amgen, Roche did not
Adaptin Bio is launching with plans to bring a bispecific T cell engager for glioblastoma, a deadly form of brain cancer, into the clinic. The company received FDA clearance to start its clinical trial, which will be run at Duke University and enroll around 25 patients. The bispecific T cell engager was developed by researchers led by John Sampson, who previously was chair of the neurosurgery department at Duke and is now dean of the University …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
